Trial Profile
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; GS 5829 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences
- 11 Jul 2022 Results from NCT02392611 and NCT02607228; assessing safety and efficacy, published in the Clinical Cancer Research
- 04 Dec 2020 Status changed from completed to discontinued.
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.